Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENTFIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL

VOLUNTARY ANNOUNCEMENTFIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL

June 25, 2024

VOLUNTARY ANNOUNCEMENTFIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL_00.png

VOLUNTARY ANNOUNCEMENTFIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL_01.png

Previous: VOLUNTARY ANNOUNCEMENT - ENLONSTOBART INJECTION OBTAINS CONDITIONAL MARKETING APPROVAL GRANTED BY NMPA

Next: TRACE-III, another important research result of CSPC Mingfule in the field of ischemic stroke treatment, was published online in the top international medical j

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat